Calcium Phosphate Stones on Topiramate for Drug-Resistant Epilepsy
The drug that finally controls her seizures is also, through the same mechanism, the reason her urine keeps forming calcium phosphate stones — and the usual fix for that biochemistry has a real paradox built into it.
Dana W., a 33-year-old graduate student, has structured her final year of coursework and thesis writing around working from home, partly by choice and partly because her neurologist advised against driving unsupervised given her seizure history. She has drug-resistant epilepsy, diagnosed at nineteen after failing three prior anticonvulsants, and has been seizure-free for the past four years on topiramate 200mg twice daily — the only regimen, after years of trial and adjustment, that has actually controlled her seizures. She passed her first kidney stone eight months ago and a second, smaller one two weeks ago, both without intervention. Basic labs today show a mild non-anion-gap metabolic acidosis with a serum bicarbonate of 20, and a 24-hour urine collection shows a persistently alkaline pH of 6.8 alongside a low urinary citrate — a pattern her neurologist had not previously connected to her anticonvulsant.
Topiramate inhibits carbonic anhydrase in the renal tubule, the same mechanism by which it modulates neuronal excitability, and that inhibition produces a mild, drug-induced renal tubular acidosis: impaired bicarbonate reabsorption drives systemic acidosis and an alkaline urine, while the acidosis itself increases proximal tubular citrate reabsorption and lowers what reaches the urine. The combination — alkaline urine with low citrate — is exactly the environment that favors calcium phosphate crystallization, and the FDA's own labeling data put the incidence of topiramate-associated kidney stones at roughly two to four times the expected background rate. The usual correction for low urinary citrate, potassium citrate, carries a genuine irony here: citrate itself is an alkali, and adding more alkali to urine that is already too alkaline for her stone type is not an unambiguous fix, even though raising citrate is the part of the drug's effect actually responsible for preventing calcium phosphate crystals from forming.
It is worth being concrete about where her own numbers sit inside that paradox, because it is narrower than it sounds. Calcium phosphate crystallization becomes the dominant risk as urine pH climbs past about 6.5, and hers already reads 6.8 — she is not near the threshold, she is over it, which is why the stones she has formed are calcium phosphate rather than the calcium oxalate that dominates almost everywhere else. Potassium citrate is being asked to raise the one parameter she is short of while pushing further the one parameter she has too much of, starting from the wrong side of the line rather than a safe distance below it. That is the whole of the decision: not whether citrate helps hypocitraturia, which it does, but whether it can be titrated to help hers without buying the correction at the price of the pH that caused her stone type in the first place.
In clinic, after her second small stone
Her low urinary citrate is the parameter I'd target directly. Citrate is a potent inhibitor of calcium phosphate crystallization on its own — it chelates urinary calcium directly — and that citrate-raising effect is well established as the dominant benefit of potassium citrate in this exact biochemical pattern. I'd start it.
I want to name the actual cause rather than just treat around it. Her acidosis, her low citrate, her alkaline urine — all of it traces to one drug's mechanism. If we can adjust her topiramate regimen safely, we're addressing the source rather than adding a second medication indefinitely to manage a side effect of the first.
I take the citrate argument seriously, but I don't think we should treat 'the drug caused this' as settled without at least considering whether the drug itself can change.
I'd slow both of you down. Her stones so far have been small and passed on their own without any intervention — nothing about her clinical course today is urgent. Potassium citrate is also an alkali, and adding more alkali to urine that's already too alkaline for calcium phosphate specifically is a real, not hypothetical, paradox, not just a footnote. And adjusting a seizure regimen that took years to stabilize isn't something to do reflexively either. I'd increase her fluids, monitor with periodic imaging, and hold both drug decisions until there's a clearer signal this is actually getting worse.
Agreed: a low, monitored dose of potassium citrate alongside increased fluid intake, with a repeat 24-hour urine collection in three months to see whether citrate rises without her urine pH climbing further.
Not agreed: the neurologist maintained that a topiramate adjustment should be reconsidered if her stone activity continues, while the nephrologist would prefer to exhaust fluid and citrate measures fully first; the clinical pharmacologist did not take a position on that later question, since it falls outside today's decision.